Cargando…

A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: Regulation of VEGF/VEGFR-2 signaling pathways

GV1001, a human telomerase reverse transcriptase catalytic subunit-derived 16-mer peptide, has been developed as a novel anticancer vaccine against various cancers including pancreatic cancer. In the current study, we demonstrate the regulatory roles and mechanisms of GV1001 in endothelial cell resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jae Hyeon, Cho, Young-Rak, Ahn, Eun-Kyung, Kim, Sunho, Han, Surim, Kim, Sung Joon, Bae, Gyu-Un, Oh, Joa Sub, Seo, Dong-Wan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526227/ https://www.ncbi.nlm.nih.gov/pubmed/36183673 http://dx.doi.org/10.1016/j.tranon.2022.101546

Ejemplares similares

Broussonin A– and B–mediated inhibition of angiogenesis by blockade of VEGFR‐2 signalling pathways and integrin β1 expression
por: Kim, Jae Hyeon, et al.
Publicado: (2022)

The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide
por: Kim, Hong, et al.
Publicado: (2016)

Novel functions for 2‐phenylbenzimidazole‐5‐sulphonic acid: Inhibition of ovarian cancer cell responses and tumour angiogenesis
por: Kim, Min Su, et al.
Publicado: (2020)

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer
por: Kim, Sejin, et al.
Publicado: (2022)

Protective effects of GV1001 on myocardial ischemia-reperfusion injury
por: Chang, Ji-Eun, et al.
Publicado: (2017)

Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice
por: Kim, Shin Hye, et al.
Publicado: (2018)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-κB/VEGF pathway
por: Park, Yong Hyun, et al.
Publicado: (2019)

GV1001 Inhibits the Severity of the Ligature-Induced Periodontitis and the Vascular Lipid Deposition Associated with the Periodontitis in Mice
por: Kim, Sharon Y., et al.
Publicado: (2023)

DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis
por: Choi, Hyeong Sim, et al.
Publicado: (2016)

SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2
por: Choi, Hyeong Sim, et al.
Publicado: (2016)

The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production
por: Choi, Jiyea, et al.
Publicado: (2015)

hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF-β signaling
por: Chen, Wei, et al.
Publicado: (2018)

Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury
por: Kwon, Hyuk Sung, et al.
Publicado: (2021)

Outcomes of Peptide Vaccine GV1001 Treatment in a Murine Model of Acute Noise-Induced Hearing Loss
por: Lee, Sang-Yeon, et al.
Publicado: (2020)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Gαs-cAMP pathway and AR-YAP1 axis
por: Kim, Ji Won, et al.
Publicado: (2021)

GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition
por: Kim, Yejin, et al.
Publicado: (2021)

The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression
por: Park, Mi Sun, et al.
Publicado: (2014)

Syntenin promotes VEGF-induced VEGFR2 endocytosis and angiogenesis by increasing ephrin-B2 function in endothelial cells
por: Tae, Nara, et al.
Publicado: (2017)

Geraniol Suppresses Angiogenesis by Downregulating Vascular Endothelial Growth Factor (VEGF)/VEGFR-2 Signaling
por: Wittig, Christine, et al.
Publicado: (2015)

Sinensetin suppresses angiogenesis in liver cancer by targeting the VEGF/VEGFR2/AKT signaling pathway
por: Li, Xiao, et al.
Publicado: (2022)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2
por: Mohamedali, Khalid A, et al.
Publicado: (2011)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Regulation of Pathologic Retinal Angiogenesis in Mice and Inhibition of VEGF-VEGFR2 Binding by Soluble Heparan Sulfate
por: Nishiguchi, Koji M., et al.
Publicado: (2010)

Coral-Derived Compound WA-25 Inhibits Angiogenesis by Attenuating the VEGF/VEGFR2 Signaling Pathway
por: Lin, Shih-Wei, et al.
Publicado: (2015)

Inhibition of VEGF(165)/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis
por: Chen, Chi-Kuan, et al.
Publicado: (2016)

OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling
por: Song, Feifei, et al.
Publicado: (2019)

SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment
por: Xie, Junye, et al.
Publicado: (2023)

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
por: Koh, Seong-Ho, et al.
Publicado: (2021)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis
por: Farzaneh Behelgardi, Maryam, et al.
Publicado: (2018)

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
por: Inderberg-Suso, Else-Marit, et al.
Publicado: (2012)

Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway
por: Tang, Ning, et al.
Publicado: (2015)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

1001 noches.
Publicado: (1945)

MONO 1001
por: Pacquet, J Y, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_3debc3le5akpae3aalp21iqqji